Abstract
Isotretinoin was initially approved by the US Food and Drug Administration (FDA) in May 1982. The prelaunch enthusiasm driven by key opinion leaders led many dermatologists in the USA to eagerly anticipate the delivery of isotretinoin to local pharmacies. Not only is isotretinoin effective in the narrowly defined approved indication for severe recalcitrant nodular acne, it is also effective in treating more moderate levels of severity, often leading to permanent remissions. Not surprisingly, the numbers of patients exposed to isotretinoin rapidly exceed those predicted by the prevalence of the narrowly defined FDA-approved severe subset of acne patients. Although the most severe subset of acne patients would be predictably mostly males, female patients soon accounted for approximately half of all exposed patients.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Lammer EF, Chen DT, Hoar RM, et al. Retinoic acid embryopathy. N Engl J Med. 1985;313:837–41.
Lammer EF, Hayes AM, Schunior A, et al. Unusual high risk for adverse outcomes of pregnancy following fetal isotretinoin exposure [Abstract]. Am J Hum Genet. 1988;43:A58.
Dai WS, LaBraico JM, Stern RS. Epidemiology of isotretinoin exposure during pregnancy. J Am Acad Dermatol. 1992;26:599–606.
Mitchell AA, Van Bennekom CM, Louik C. A pregnancy prevention program in women of childbearing age receiving isotretinoin. N Engl J Med. 1995;333:101–6.
Koren G, Avner M, Shear N. Generic isotretinoin: a new risk for unborn children. CMAJ. 2004;170:1567–8.
Zouboulis CC. Isotretinoin revisited: pluripotent effects on human sebaceous gland cells. J Invest Dermatol. 2006;126:2154–6.
Weinstock MA, Bingham SF, Lew RA, et al. Topical tretinoin therapy and all-cause mortality. Arch Dermatol. 2009;145:18–24.
Rosenberg EW, Skinner Jr RB. Topical retinoids: another piece for the retinoid-cigarette-lung cancer puzzle? J Thorac Oncol. 2006;1(7):732.
Strauss JS, Krowchuk DP, Leyden JJ, American Academy of Dermatology, et al. Guidelines of care for acne vulgaris management. J Am Acad Dermatol. 2007;56:651–63.
Harms M. Systemic isotretinoin (active ingredient of Roaccutane®): a unique therapeutic effect and its implications in the pathogenesis of acne. 3rd ed. Basel: Editiones Roche; 1994. 93 p.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Wilkin, J. (2014). Oral Isotretinoin: The US Approach. In: Zouboulis, C., Katsambas, A., Kligman, A. (eds) Pathogenesis and Treatment of Acne and Rosacea. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-69375-8_63
Download citation
DOI: https://doi.org/10.1007/978-3-540-69375-8_63
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-69374-1
Online ISBN: 978-3-540-69375-8
eBook Packages: MedicineMedicine (R0)